Navigation Links
Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
Date:11/20/2009

SEATTLE, Nov. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Ninth Circuit Court of Appeals reversed a U.S. District Court order and ruled that CTI should be allowed to pursue all of its claims against The Lash Group, sending the case back to the District Court for trial. CTI filed a complaint against The Lash Group, CTI's former third-party reimbursement consultant for CTI's product TRISENOX, in 2007 seeking $22.8 million in damages for expenses already incurred related to the investigation, defense and a settlement of claims by the U.S. government concerning Medicare reimbursement for TRISENOX and other business losses.

In 2007, CTI settled the claims by the U.S. government without admitting liability and filed a lawsuit including claims that The Lash Group had breached its contractual obligations to CTI as related to its services, as well as an obligation to indemnify the company for damages related to the settlement. CTI sold TRISENOX in 2005 to Cephalon, Inc.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the securities of CTI. Specifically, the risks and uncertainties include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and the possibility that CTI may not be successful in obtaining a judgment for damages and that The Lash Group may appeal any award given, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.



Media Contact:                      Investors Contact:

Dan Eramian                         Ed Bell
T: 206.272.4343                     T: 206.272.4345
C: 206.854.1200                     Lindsey Jesch Logan
F: 206.272.4434                     T: 206.272.4347
E: deramian@ctiseattle.com          F: 206.272.4434
www.celltherapeutics.com/press_room E: invest@ctiseattle.com
                                    www.celltherapeutics.com/investors


SOURCE Cell Therapeutics, Inc.


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 21, 2017 , ... Benchworks CEO Thad L. ... Forum on March 23-24 in San Diego. The event is a gathering of ... , Benchworks Vice President Christian Meyer will also participate in the forum. Participants ...
(Date:3/22/2017)... WI (PRWEB) , ... March 22, 2017 , ... The ... scientific research agencies as outlined in the Administration’s recently published fiscal year 2018 budget ... the National Institutes of Health (NIH) by $5.8 billion or roughly 20% of its ...
(Date:3/22/2017)... March 22, 2017   Invitae Corporation ... information companies, today announced the availability of a ... Spinal Muscular Atrophy (SMA) , a neuromuscular disease ... disorders among infants as well as a significant ... new test, announced during the American College of ...
(Date:3/20/2017)... CA (PRWEB) , ... March 20, 2017 , ... ... require expensive and laborious sample preparation methods in order to reduce the impact ... underappreciated outside of the area of elemental analysis. , This presentation will ...
Breaking Biology Technology:
(Date:3/7/2017)...   HireVue , the leading provider of video ... best talent, faster, today announced the additions of ... Diana Kucer as Chief Marketing Officer (CMO). ... poised to drive continued growth in the company,s new ... record bookings in 2017. "Companies worldwide turn ...
(Date:3/2/2017)... March 2, 2017 Summary This report ... and its partnering interests and activities since 2010. ... Read the full ... Alliance since 2010 report provides an in-depth insight into the ... companies. On demand company reports are prepared upon ...
(Date:3/2/2017)... March 2, 2017 Who risk to be ... Download the full report: https://www.reportbuyer.com/product/4313699/ WILL ... SENSOR FIELD? Fingerprint sensors using capacitive technology represent ... sensor vendor Idex forecasts an increase of 360% of ... and of the fingerprint sensor market between 2014 and ...
Breaking Biology News(10 mins):